United States - English - NLM (National Library of Medicine)

auromedics pharma llc - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 1 mg in 1 ml - granisetron hydrochloride injection, usp  is a serotonin-3 (5-ht3 ) receptor antagonist indicated for: - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. - the prevention and treatment of postoperative nausea and vomiting in adults. as with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided during the postoperative period, granisetron hydrochloride injection usp is recommended even where the incidence of postoperative nausea and/or vomiting is low.  granisetron hydrochloride injection is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis, shortness of breath, hypotension, urticaria) to the drug or to any of its components. teratogenic effects p regnancy category b reproduction studies have been performed in pregnant rat

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg/ml - concentrate for injection - 1 mg/ml - active: granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg/ml excipient: citric acid monohydrate hydrochloric acid sodium chloride sodium hydroxide water for injection - adults: granisetron is indicated for the prevention of nausea and vomiting induced by cytotoxic chemotherapy. the prevention of nausea and vomiting induced by radiotherapy. the prevention and treatment of postoperative nausea and vomiting. children: granisetron is indicated for the prevention of nausea and vomiting induced by cytotoxic chemotherapy.

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 1 mg - granisetron hydrochloride tablets are indicated for the prevention of: granisetron hydrochloride is contraindicated in patients with known hypersensitivity to the drug or any of its components.

United States - English - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 1 mg - granisetron hydrochloride tablets usp are indicated for the prevention of: nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. granisetron hydrochloride tablets are contraindicated in patients with known hypersensitivity to the drug or any of its components.

Canada - English - Health Canada

natco pharma (canada) inc - granisetron (granisetron hydrochloride) - tablet - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

Canada - English - Health Canada

omega laboratories limited - granisetron (granisetron hydrochloride) - liquid - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

Canada - English - Health Canada

strides pharma canada inc - granisetron (granisetron hydrochloride) - solution - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - granisetron hydrochloride, quantity: 1.12 mg/ml (equivalent: granisetron, qty 1 mg/ml) - injection, solution - excipient ingredients: water for injections; citric acid monohydrate; sodium hydroxide; sodium chloride; hydrochloric acid - adults:,kytril (tablets and injection) is indicated for use in adults for:,the prevention of nausea and vomiting induced by cytotoxic chemotherapy; the prevention of nausea and vomiting induced by radiotherapy. kytril (injection) is also indicated for use in the treatment of nausea and vomiting induced by cytotoxic chemotherapy; and prevention and treatment of post-operative nausea and vomiting.,paediatric:,kytril injection is indicated for the prevention of nausea and vomiting induced by cytotoxic chemotherapy.

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron hydrochloride injection, usp is a serotonin-3 (5-ht3 ) receptor antagonist indicated for: - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. granisetron hydrochloride injection is contraindicated in patients with known hypersensitivity (eg. anaphylaxis, shortness of breath, hypotension, urticaria) to the drug or to any of its components. teratogenic effects pregnancy category b reproduction studies have been performed in pregnant rats at intravenous doses up to 9 mg/kg/day (54 mg/m2 /day, 146 times the recommended human dose based on body surface area) and pregnant rabbits at intravenous doses up to 3 mg/kg/day (35.4 mg/m2 /day, 96 times the recommended human dose based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to granisetron. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - granisetron hydrochloride - oral tablet - 1mg